Letter to the Editor regarding Response to "Letter to Editor: "Real-World Effectiveness of Ensitrelvir in Reducing Severe Outcomes in Outpatients at High Risk for COVID-19"
Infect Dis Ther
.
2024 Nov;13(11):2463-2467.
doi: 10.1007/s40121-024-01054-6.
Epub 2024 Sep 27.
Authors
Takahiro Takazono
1
,
Satoki Fujita
2
,
Takuji Komeda
3
,
Shogo Miyazawa
3
,
Yuki Yoshida
3
,
Yoshitake Kitanishi
3
,
Masahiro Kinoshita
4
,
Satoshi Kojima
4
,
Huilian Shen
4
,
Takeki Uehara
5
,
Naoki Hosogaya
1
,
Naoki Iwanaga
1
,
Hiroshi Mukae
1
6
Affiliations
1
Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
2
Data Science Department, Shionogi & Co., Ltd., Osaka, Japan.
[email protected]
.
3
Data Science Department, Shionogi & Co., Ltd., Osaka, Japan.
4
Medical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan.
5
Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan.
6
Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
PMID:
39331323
PMCID:
PMC11499536
DOI:
10.1007/s40121-024-01054-6
No abstract available
Keywords:
COVID-19; Ensitrelvir; Hospitalization; Japanese nationwide database.
Publication types
Letter